Progression of a series of patients with relapsing-remitting multiple sclerosis treated for 7 years with natalizumab using the “no evidence of disease activity” parameter by A. Pato Pato, E. Costa Arpín, A. Rodríguez Regal, I. Rodríguez Constenla, I. Cimas Hernando, I. Muñoz Pousa, L. Naya Ríos, J.R. Lorenzo González, M.C. Amigo Jorrín, J.M. Prieto González

Get full text